

This article was downloaded by: [UQ Library]

On: 13 July 2015, At: 07:00

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: 5 Howick Place, London, SW1P 1WG



## Drug Delivery

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/idrd20>

### Correlation Between the Transdermal Permeation of Ketoprofen and its Solubility in Mixtures of a pH 6.5 Phosphate Buffer and Various Solvents

G. C. Ceschel<sup>a</sup>, P. Maffei<sup>a</sup> & S. Lombardi Borgia<sup>a</sup>

<sup>a</sup> Pharmaceutical Sciences Department, Bologna University, Bologna, Italy

Published online: 04 May 2015.

To cite this article: G. C. Ceschel, P. Maffei & S. Lombardi Borgia (2002) Correlation Between the Transdermal Permeation of Ketoprofen and its Solubility in Mixtures of a pH 6.5 Phosphate Buffer and Various Solvents, Drug Delivery, 9:1, 39-45

To link to this article: <http://dx.doi.org/10.1080/107175402753413163>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

# Correlation Between the Transdermal Permeation of Ketoprofen and its Solubility in Mixtures of a pH 6.5 Phosphate Buffer and Various Solvents

G. C. Ceschel, P. Maffei, and S. Lombardi Borgia

Pharmaceutical Sciences Department, Bologna University, Bologna, Italy

The passage of a drug through the skin is directly proportional to the concentration of the drug in the donor phase and to the permeability coefficient constant  $K_p$ .  $K_p$  is determined essentially by two factors: the dissolution of the drug in the stratum corneum (measured by the partition coefficient  $P$ ) and the diffusion in the same stratum (measured by the diffusion constant  $D$ ). In our study, several saturated solutions of ketoprofen in mixtures of a pH 6.5 phosphate buffer and various co-solvents were studied to find correlations between the solubility of the ketoprofen in the mixtures and its permeation parameters in *in vitro* permeation studies with Franz cells. The results show that  $D$  does not change in the different mixtures; the diffusion of the drug into the stratum corneum is not influenced by the presence of the co-solvents, whereas the partition coefficient is strongly influenced. In particular,  $K_p$  and  $P$  were found to be inversely proportional to solubility, meaning that when the co-solvent increases the solubility, the partition of the drug and consequently  $K_p$  decrease. These findings were confirmed in some developed gels, and the developed gels were found to enhance the ketoprofen permeation with respect to the formulation in a commercial Fastum<sup>®</sup> gel.

**Keywords** Diffusion Constant, Ketoprofen, Partition Coefficient, Permeability, Transdermal Permeation

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic actions. It is equally or more potent than other NSAIDs with respect to anti-inflammatory and analgesic activity. But it causes some gastrointestinal side effects such as nausea, dyspepsia, diarrhea, constipation, and some renal side effects, like other NSAIDs (Hersh et al. 2000; Saxena and Saxena 1978). Therefore, transdermal drug delivery would be an ideal route for the administration of this drug, to avoid the

oral side effects and provide relatively constant drugs levels at the application site for prolonged periods. However, transdermal administration of many drugs is often precluded because of the stratum corneum barrier.

In the formulation of vehicles for topical administration, the efficacy of the dosage form often depends on the composition of the vehicle (Goto et al. 1983; Obata et al. 1993; Ostrenga, Steinmetz, and Poulsen 1971a, 1971b; Ross and Shah 2000). Percutaneous absorption is a passive diffusion process determined essentially by two factors: the dissolution and the diffusion of the drug into the stratum corneum. The contribution of each of these is expressed in Fick's equation in terms of the partition coefficient of the drug between the stratum corneum and the donor phase ( $P$ ) and the diffusion constant ( $D$  cm<sup>2</sup>/h) of the drug in the barrier (Dugard and Scott 1986).

$P$  is an index of the affinity of the drug for the vehicle or the skin and can be optimized by decreasing its solubility in the vehicle whereas  $D$  is related to the characteristics of the drug (Cordero et al. 1997). It could change using enhancers that fluidize the lipids or induce structural changes in proteins of the stratum corneum (Kommuru, Khan, and Reddy 1998; Rhee et al. 1999; Walter, Olejnik, and Harris 1984; Williams and Barry 1991; Yamane, Williams, and Barry 1994) or using cosolvents that increase the partition tendencies of the permeant in the rate-limiting lipid phase (Kurihara-Bergstrom, Flynn, and Higuchi 1986; Okamoto, Hashida, and Sezaki 1988).

The aim of our study was to find any correlation between the permeability of ketoprofen through the skin and its solubility in mixtures of water and co-solvents and to choose the co-solvent that best enhances the permeability of ketoprofen in the development of hydrophilic topicals.

To do this, we performed *in vitro* infinite dose permeation studies on standard Franz diffusion cells using ketoprofen suspensions in mixtures of water and co-solvents. The effectiveness of the studies on the suspensions was also tested in developing hydrophilic gels using some of the co-solvents.

Received 10 September 2001; accepted 6 October 2001.

Address correspondence to dott. P. Maffei, Pharmaceutical Sciences Department, Via S. Donato 19/2, 40128 Bologna, Italy. E-mail: paolam@biofarm.unibo.it

## MATERIALS AND METHODS

### Chemicals

Ketoprofen was a gift from Aldrich (Milan, Italy), 1,2-Propylen glycol was obtained from the Fluka Chemical Company (Milan, Italy), ethoxyethylendiglycol Transcutol<sup>®</sup> from Gattefossé (Saint-Priest, France), ethyl alcohol absolute, isopropyl alcohol, glycerol 90%, and PEG 400 from Carlo Erba (Rodano, Italy). All the materials were used as received.

### Analyses

Ketoprofen in samples was determined using a HPLC device (Model 305, Gilson,) equipped with a variable-wavelength ultraviolet detector (model Spectra 200, Spectra-Physics.). A Nova-Pak C18 (150 × 3.9 mm, 4 μm, Waters) column was used. Elution was carried out at room temperature with a mobile phase consisting of phosphate buffer 0.025 M adjusted to pH 3 with phosphoric acid and acetonitrile (5:5, v/v); the injecting volume was 20 μl. The flow rate was 1 ml/min, and the detection was at 276 nm. In this condition the retention time of ketoprofen was 7.50 min.

### Solubility Studies

The solubilities of ketoprofen in the mixtures made up of a pH 6.5 phosphate buffer 0.5 M and various co-solvents at different concentrations were determined at 37°C. Excess drug was added to the systems at room temperature, heated to 50°C to dissolve the drug, and then equilibrated at 37°C ± 0.5°C for 24 h. Aliquots of the saturated systems were filtered through Millipore filters (W-13-2, Tosoh Company,) diluted with mobile phase, and analyzed by HPLC. Saturated solutions were used to ensure equal thermodynamic activity.

### Tissue Preparation

Porcine skin is largely used for *in vitro* experiments because it is similar to the human epidermis as demonstrated by differential scanning calorimetric studies in which the porcine and the human stratum corneum showed a very similar thermogram (Potts et al. 1991) and by permeation studies that showed that porcine skin offers similar resistance to permeation as human skin (Walker et al. 1997; Wester et al. 1998). Full-thickness skin with a fair amount of underlying connective tissue was surgically removed from the ears of freshly killed male pigs (30–50 Kg) obtained, on each study day, from a local slaughter house (CLAI, Imola, Italy). The skin was placed in ice-cold phosphate buffered saline, pH 7.4. The connective tissue of the skin was carefully removed using fine-point forceps and surgical scissors. The cleaned membrane was then placed in ice-cold PBS until it was mounted in the diffusion cells.

### *In vitro* Diffusion Study

The *in vitro* diffusion studies were carried out in standard Franz diffusion cells having 0.64 cm<sup>2</sup> diffusion area (Franz 1975;

Friend 1992). The receptor compartment has a volume of 4.8 ml and was maintained at 37°C by a water bath, circulator, and a jacket surrounding the cells. The cells were filled with fresh PBS. The solution in the receptor compartments was continuously stirred at 600 rpm using a Tefloncoated magnetic stirrer. The porcine skin, 1 ± 0.1 mm thick, was clamped between the donor and receiving compartments. Then 1 ml of the saturated solutions was placed in the donor compartment. We also tested 1 ml of developed gels and Fastum<sup>®</sup> gel.

The amount of ketoprofen diffused through porcine skin was determined by removing aliquots of 2 ml from the receptor compartments using a syringe and immediately replacing with the same volume of PBS (kept at 37°C). The sampling schedule was 0.5, 1, 2, 4, 6, and 8 h. All experiments were carried out 6 times.

### Data Analysis

The transport of drugs across the skin barrier may be considered a process of passive diffusion. The *in vitro* skin flow was determined from Fick's law of diffusion:

$$J_s = (1/A)(dM/dt) = K_p \Delta C, \quad [1]$$

where  $J_s$  is the skin flow ( $\mu\text{g cm}^{-2} \text{h}^{-1}$ ),  $dM/dt$  is the amount of drug permeated per unit of time,  $A$  is the diffusion area ( $\text{cm}^2$ ),  $K_p$  is the permeability coefficient ( $\text{cm h}^{-1}$ ), and  $\Delta C$  is the concentration gradient. In all the experiments, the concentrations in the donor cell remained constant, the receiver cell concentrations did not exceed 10% of the donor cell concentrations, and  $\Delta C$  was assumed to be equal to the donor cell concentrations. The steady-state flux  $J_s$  was determined from the slope of the linear portion of the cumulative amount permeated per unit area versus time plot. The lag time was determined by extrapolating the linear portion of the curve to the abscissa.

The  $K_p$  value is also:

$$K_p = (D * P)/h \quad [2]$$

where  $D$  is the diffusion coefficient of the drug into the stratum corneum,  $P$  is the partition coefficient of the drug between stratum corneum and vehicle of administration, and  $h$  is the stratum corneum thickness.  $D$  was approximated indirectly from the lag time:

$$\text{Lag time} = h^2/6D. \quad [3]$$

Knowing  $K_p$  and  $D$ , it was then possible to determine the value of  $P$  (Ostrenga, Steinmetz, and Poulsen 1971).

## RESULTS AND DISCUSSION

In all experiments, the permeation profiles showed a curved portion, corresponding to a lag phase, followed by a linear




FIG. 1. Permeation profiles of ketoprofen from the saturated solutions.

portion, which means that an apparent steady state of ketoprofen penetration was attained (Figure 1). The solubilities of the ketoprofen in the different mixtures and the calculated permeation parameters are shown in Table 1. When statistical analysis was carried out for D values, statistical significance ( $p < 0.05$ ) was not recognized. This means that the presence of the cosolvents does not change the diffusion rate of ketoprofen.

The graph of permeability constant  $K_p$  values versus ketoprofen solubilities in the saturated solutions is showed in Figure 2 and the partition P values versus ketoprofen solubilities is showed in Figure 3. The correlation between the variables was found to be high in the two graphs:  $R^2 = 0.86$  for  $K_p$  and  $R^2 = 0.77$  for P. Considering that D is constant in all the tested mixtures, the variation in permeability constant was due




FIG. 2. Permeability constant  $K_p$  values versus ketoprofen solubilities in the saturated solutions.




FIG. 3. Partition P values versus ketoprofen solubilities in the saturated solutions.

**TABLE 1**  
Solubilities and permeation parameters of the ketoprofen in all the tested mixtures

(PB)	Solubility ( $\mu\text{g/ml}$ )	$K_p \cdot 10^{-3}$ ( $\text{cm/h}$ )	$J$ ( $\mu\text{g}/$ $\text{cm}^2 \text{ h}$ )	$(D \cdot 10^{-3})$ ( $\text{cm}^2/\text{h}$ )	$P \cdot 10^{-3}$	Lag time (h)
Phosphate buffer pH 6.5	9900.56 sd 20.23	3.848 sd 0.213	38.102 sd 2.11	36.332 sd 4.63	10.592 sd 0.587	1.65 sd 0.36
PB and ethanol 10% v/v	16647.58 sd 100.23	4.737 sd 0.220	78.859 sd 3.66	36.062 sd 5.05	13.136 sd 0.610	1.66 sd 0.33
PB and ethanol 20% v/v	21193.47 sd 56.33	3.078 sd 0.194	65.223 sd 4.12	40.028 sd 5.75	7.688 sd 0.486	1.50 sd 0.29
PB and ethanol 40% v/v	71151.15 sd 78.98	1.386 sd 0.016	98.630 sd 1.11	34.801 sd 5.38	3.983 sd 0.045	1.72 sd 0.31
PB and ethanol 60% v/v	60306.15 sd 89.22	1.406 sd 0.054	84.766 sd 3.23	40.928 sd 3.70	3.434 sd 0.131	1.47 sd 0.45
PB and ethanol 80% v/v	391001.7 sd 102.52	0.147 sd 0.007	57.500 sd 2.55	32.75 sd 3.27	0.449 sd 0.020	1.83 sd 0.51
PB and ethanol 100% v/v	305985.1 sd 125.63	0.079 sd 0.009	24.172 sd 2.62	27.868 sd 5.05	0.283 sd 0.031	2.15 sd 0.33
PB and isopropyl alcohol 10% v/v	12556.02 sd 12.35	3.971 sd 0.157	49.863 sd 1.97	37.355 sd 0.02	9.875 sd 0.420	1.52 sd 0.23
PB and isopropyl alcohol 20% v/v	25797.26 sd 35.26	1.875 sd 0.142	48.380 sd 3.66	36.072 sd 5.21	5.199 sd 0.393	1.66 sd 0.32
PB and glycerol 10% v/v	7433.975 sd 32.32	7.404 sd 0.447	55.044 sd 3.32	34.656 sd 5.05	21.365 sd 1.289	1.73 sd 0.33
PB and glycerol 20% v/v	9209.467 sd 26.21	2.187 sd 0.446	20.145 sd 4.11	39.388 sd 7.94	5.554 sd 1.133	1.52 sd 0.21
PB and glycerol 40% v/v	5570.873 sd 98.23	5.652 sd 0.555	31.489 sd 3.09	37.998 sd 9.80	14.876 sd 1.460	1.58 sd 0.17
PB and glycerol 60% v/v	5697.315 sd 53.21	4.766 sd 0.563	27.156 sd 3.21	51.344 sd 15.15	9.283 sd 1.097	1.17 sd 0.11
PB and Transcutol <sup>®</sup> 10% v/v	15101.35 sd 56.22	3.707 sd 0.154	55.988 sd 2.33	49.121 sd 10.42	7.548 sd 0.314	1.22 sd 0.16
PB and Transcutol <sup>®</sup> 20% v/v	23402.25 sd 59.06	3.356 sd 0.133	78.531 sd 3.11	33.625 sd 6.41	9.98 sd 0.395	1.78 sd 0.26
PB and propylene glycol 10% v/v	13322.99 sd 52.01	4.02 sd 0.161	53.555 sd 2.14	40.493 sd 7.58	9.927 sd 0.397	1.48 sd 0.22
PB and propylene glycol 20% v/v	14907.53 sd 32.02	3.507 sd 0.142	52.286 sd 2.11	37.256 sd 5.05	9.414 sd 0.380	1.61 sd 0.33
PB and PEG 400 10%	17967.18 sd 33.01	2.14 sd 0.168	38.453 sd 3.01	54.167 sd 5.38	3.951 sd 0.309	1.11 sd 0.31
PB and PEG 400 20%	22286 sd 21.22	1.202 sd 0.134	26.786 sd 2.98	36.258 sd 7.25	3.315 sd 0.369	1.65 sd 0.23

to a change in partition coefficient that is itself shown to be inversely proportional to the solubility. In fact, the exponent of the x variable was found to be  $-0.92$  for  $K_p$  and  $-0.88$  for  $P$  correlations meaning that an inverse proportionality was found.

The highest  $K_p$  was obtained using glycerol at 10% concentration, followed by glycerol at 40% and 60% concentration; in

all these mixtures the solubility of ketoprofen was low, between 5570 and 7433  $\mu\text{g/ml}$ .

The highest flux was obtained using ethanol at a concentration of 40% (98.63  $\mu\text{g/cm}^2\text{h}$ ), followed by ethanol at 60% (84.76  $\mu\text{g/cm}^2\text{h}$ ), and 10% concentration (78.85  $\mu\text{g/cm}^2\text{h}$ ). In these mixtures, the solubility of ketoprofen was high (between 60306 and 71151  $\mu\text{g/ml}$ ) with the exception of ethanol at 10%

**TABLE 2**  
Composition of developed gels

	PB gel	Isopropyl alcohol 10% gel	Isopropyl alcohol 20% gel	Ethanol 10% gel	Ethanol 40% gel	Transcutol 10% gel
Ketoprofen	1% w/v	1% w/v	1% w/v	1% w/v	1% w/v	1% w/v
Carbopol 940P	2% w/v	2% w/v	2% w/v	2% w/v	2% w/v	2% w/v
Solvent and its concentration	—	Isopropyl alcohol 10% v/v	Isopropyl alcohol 20% v/v	Ethanol 10% v/v	Ethanol 40%	Transcutol 10%
pH 6.5 phosphate buffer	To 100%	To 100%	To 100%	To 100%	To 100%	To 100%

concentration in which the solubility of ketoprofen is lower (16647 µg/ml).

These results suggest that to have a high flux it is necessary to use a solvent that can solubilize the ketoprofen. But if the ketoprofen concentration is to be low in the topical formulation, the flux from an ethanol mixture would be low because otherwise the flux in the experiments was found to be high, the Kp was low. The results show that the solvents can modulate the partition of the drug and thus the drug flux.

To test these findings, we developed gels using the same polymer (carbopol 940 P at 2% w/w concentration) and various solvents. The developed gel compositions are shown in Table 2. We developed formulations with the drug completely solubilized in the gel matrix at 1% w/v concentration because we wanted to test solvents with a large range of Kp values. We chose as co-solvent in the hydrophilic gels, isopropyl alcohol at 10% and 20% concentrations because they had very different Kp values, although they had almost the same composition. We used ethanol at 10% concentration because it showed the higher Kp than the one shown by the solvents that were able to solubilize ketoprofen at a concentration higher than 1%. We also used ethanol at 40% to simulate the commercial Fastum gel formulation whose composition is shown in Table 3. We used Transcutol at 10% of concentration because it was found to be a

permeation enhancer (Harrison et al. 1996). We made a gel without co-solvent to establish the effect of the various solvents used. We also performed an in vitro permeation study on Fastum gel in which ketoprofen was at 2.5% of w/w concentration. The permeation profiles are shown in Figure 4 while the corresponding fluxes are presented in Table 4 where the enhancer effect (ER) of the polymer carbopol 940 P is also represented. ER was calculated from the following equation:

$$ER = Kp \text{ of gel} / Kp \text{ of saturated solution} \quad [4]$$

The fluxes from the gels were different with respect to the saturated solution because the concentrations were different. The highest flux was obtained with the gel at 10% ethanol concentration, followed by the gel containing isopropyl alcohol at 10% concentration and the gel without co-solvents.

From the results of the permeability coefficients, all the developed gels showed an enhancer effect with respect to the saturated solution meaning that carbopol 940 P enhances drug permeation. The enhancer effect of the carbopol 940 P was essentially constant in all the different gels—between 1.286 and 1.604.

We found that the ratio between Kp values of the gel containing 10% isopropyl alcohol concentration and the gel containing 20% concentration of the same solvent was almost the same as the ratio between the Kp values of the corresponding saturated solutions (1.81 for the gels and 2.12 for the saturated solutions). The similarity of the ratios between the Kp of the gels and of the saturated solutions confirms that the differences in the fluxes of the saturated solutions are not due to an effect on the drug diffusion, but from the partition of the drug into the stratum corneum because the two mixtures of solvents act very differently on the drug solubility.

This result clearly demonstrates that the Kp and thus the flux can be easily modulated using a co-solvent that changes the

**TABLE 3**  
Fastum gel composition

Components	Composition
Ketoprofen	2.5 w/w
Carbopol 940P	2 w/w
Ethanol	40 v/w
p-hydroxy benzoic esters	0.1 w/w
Neroli essence	0.05 v/w
Lavander essence	0.1 v/w
Diethanol amine	1.35 w/w
Distilled water	To 100%




FIG. 4. Permeation profiles of ketoprofen from the developed gels and from Fastum gel.

partition of the drug into the stratum corneum. The flux and  $K_p$  of the gel with ethanol at 10% concentration, with Transcutol at 10%, with isopropyl alcohol at 10%, and of the gel without co-solvent are almost the same and, in parallel, also the ketoprofen solubility in these mixtures is the same. From these results we conclude that Transcutol does not have any enhancer effect on the ketoprofen permeation.

The ketoprofen flux from the gel containing ethanol at 40% concentration presents the lowest flux. Its  $K_p$  value is also the lowest, and the ratio between the  $K_p$  values of the gel with 40% ethanol concentration and the gel without co-solvent is not different from the ratio between the  $K_p$  of the corresponding saturated solutions (0.41 and 0.36).

The flux from the Fastum gel is not very high considering that it has a concentration of ketoprofen of 2.5% w/w. Otherwise, its  $K_p$  is the same as the developed gel containing 40% ethanol concentration. The interesting finding is that the flux from Fastum gel, which has the highest drug concentration, is not the highest and so it is possible to improve the ketoprofen

flux by choosing solvents that enhance the drug partition into the stratum corneum.

## CONCLUSION

From our results we found that the permeation of ketoprofen can be modulated using various co-solvents. Since  $D$  values of the in vitro permeation studies of the saturated solutions are not significantly altered in the tested mixtures, the variation in permeability coefficient of ketoprofen across skin is a result of a variation in partitioning of the drug from the vehicle into the stratum corneum.

These findings are confirmed in gels that were formulated using co-solvents that solubilize the drug with a large range of concentrations.

The present investigation demonstrates that the permeation ability of ketoprofen across skin can be successfully predicted from the knowledge of only the physicochemical parameter of solubility into an aqueous mixture of phosphate buffer and a

TABLE 4  
Fluxes, permeability coefficients, and enhancer effects of the developed gel and of the Fastum gel

	PB gel	Isopropylic alcohol 10% gel	Isopropylic alcohol 20% gel	Ethanol 10% gel	Ethanol 40% gel	Transcutol 10% gel	Fastum gel
Flux ( $\mu\text{g}/\text{cm}^2 \text{ hr}$ )	49.479	54.615	30.078	64.063	20.117	50.391	47.205
	sd 4.251	sd 4.561	sd 3.65	sd 5.23	sd 1.98	sd 4.568	sd 5.012
$K_p \cdot 10^{-3}$	4.948	5.462	3.008	6.406	2.012	5.039	4.721
ER	1.286	1.375	1.604	1.352	1.451	1.359	—

co-solvent. This is possible because the permeability constant for ketoprofen is inversely proportional to the solubility in the vehicle. Moreover, in the developed gels, we obtained a flux through the skin higher than Fastum<sup>®</sup> gel, which has a concentration 2.5 times more.

## REFERENCES

- Cordero, J. A., Alarcon, L., Escribano, E., Obach, R., and Domenech, J. 1997. A comparative study of the transdermal penetration of a series of nonsteroidal anti-inflammatory drugs. *J. Pharm. Sci.* 86:503–507.
- Dugard, P. H., and Scott, R. C. 1986. A method of predicting percutaneous absorption rates from vehicle to vehicle: an experimental assessment. *Int. J. Pharm.* 28:219–227.
- Franz, T. J. 1975. Percutaneous absorption. On the relevance of in vitro data. *J. Invest. Dermatol.* 64:190–196.
- Friend, D. R. 1992. In vitro skin permeation techniques. *J. Cont. Release.* 18:235–248.
- Goto, S., Uchida, T., Lee, C. K., Yasutake, T., and Zhang, J. B. 1983. Effect of various vehicles on ketoprofen permeation across excised hairless mouse skin. *J. Pharm. Sci.* 82:959–963.
- Harrison, J. E., Watkinson, A. C., Green, D. M., Hadgraft, J., and Brain, K. 1996. The relative effect of Azone and Transcutol on permeant diffusivity and solubility in human stratum corneum. *Pharm. Res.* 13:542–546.
- Hersh, E. V., Moore, P. A., and Ross, G. C. 2000. Over-the-counter analgesics and antipyretics: a critical assessment. *Clin. Ther.* 22:500–548.
- Kommuru, T. R., Khan, M. A., and Reddy, I. K. 1998. Racemate and enantiomers of ketoprofen: phase diagram, thermodynamic studies, skin permeability, and use of chiral permeation enhancers. *J. Pharm. Sci.* 87:833–840.
- Kurihara-Bergstrom, T., Flynn, G. L., and Higuchi, W. I. 1986. Physicochemical study of percutaneous absorption enhancement by dimethyl sulfoxide: kinetic and thermodynamic determinants of dimethyl sulfoxide mediated mass transfer of alkanols. *J. Pharm. Sci.* 75:479–486.
- Obata, T., Takayama, K., Maitani, Y., Machida, Y., and Nagai, T. 1993. Effect of ethanol on skin permeation of nonionized and ionized diclofenac. *Int. J. Pharm.* 89:191–198.
- Okamoto, H., Hashida, M., and Sezaki, H. 1988. Structure-activity relationship of 1-alkyl or 1-alkenylacycloalkanon e derivatives as percutaneous penetration enhancers. *J. Pharm. Sci.* 77:418–424.
- Ostrega, J., Steinmetz, C., and Poulsen, B. 1971a. Significance of vehicle composition I: Relationship between topical vehicle composition skin penetrability and clinical efficacy. *J. Pharm. Sci.* 60:1175–1179.
- Ostrega, J., Steinmetz, C., Poulsen B., and Yett, S. 1971b. Significance of vehicle composition II: Prediction of optimal vehicle composition. *J. Pharm. Sci.* 60:1180–1183.
- Potts, R. O., Golden, G. M., Francoer, M. L., Mak, V. H. W., and Guy, R. H. 1991. Mechanism and enhancement of solute transport across the stratum corneum. *J. Cont. Release* 15:249–260.
- Rhee, G. J., Woo, J. S., Hwang, S. J., Lee, Y. W., and Lee, C. H. 1999. Topical oleo-hydrogel preparation of ketoprofen with enhanced skin permeability. *Drug Dev. Ind. Pharm.* 25:717–726.
- Ross, J. S., and Shah, J. C. 2000. Reduction in skin permeation of *N,N*-diethyl-*m*-toluamide (DEET) by altering the skin/vehicle partition coefficient. *J. Cont. Release* 67:211–221.
- Saxena, R. P., and Saxena, U. 1978. A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease. *Curr. Med. Res. Opin.* 5: 484–488.
- Walker, M., Hulme, T. A., Rippon, M. G., Walmsley, R. S., Gunnigle, S., Lewin, M., and Winsey, S. 1997. In vitro models for the percutaneous delivery of active tissue repair agents. *J. Pharm. Sci.* 86:1379–1384.
- Walter, K. A., Olejnik, O., and Harris, S. 1984. Influence of nonionic surfactant on the permeability of ionized molecules through hairless mouse skin. *Int. Pharm. Pharmacol.* 36:78–80.
- Wester, R. C., Melendres, J., Sedik, L., Maibach, H., and Riviere, J. E. 1998. Percutaneous absorption of salicylic acid, theophylline, 2,4-dimethylamine, diethyl hexyl phthalic acid, and p-aminobenzoic acid in the isolated perfused porcine skin flap compared to man in vivo. *Toxicol. Appl. Pharmacol.* 151:159–165.
- Williams, A. C., and Barry, B. W. 1991. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. *Pharm. Res.* 8:17–24.
- Yamane, M. A., Williams, C., and Barry, B. W. 1994. Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. *J. Pharm. Pharmacol.* 47:978–989.